MARQIBO has different dosage recommendations than vincristine sulfate injection

The first and only liposome-encapsulated vincristine

  • MARQIBO is a sphingomyelin/cholesterol-based liposome–encapsulated vincristine1

 

Encapsulated formulation requires different dosing

The recommended dose of MARQIBO is 2.25 mg/m2 intravenously over 1 hour once every 7 days.1 A dose of MARQIBO is calculated based on the patient’s actual body surface area (BSA).
Select Important Safety Information

  • MARQIBO is for intravenous use only—fatal if given by other routes. Intrathecal use is fatal
  • Extravasation causes tissue injury. If extravasation is suspected, discontinue infusion immediately and consider local treatment measures

Examples of dosing calculations

  • MARQIBO has different dosage recommendations than vincristine sulfate injection. Verify drug name and dose prior to preparation and administration to avoid overdosage1
  • Please see below for recommended dose modifications for peripheral neuropathy resulting from MARQIBO1
  • MARQIBO takes approximately 60 to 90 minutes to prepare. The preparer should have dedicated uninterrupted time to prepare MARQIBO due to the extensive monitoring of temperature and time required for the preparation. For a full list of preparation steps, please see the full Prescribing Information1
  • Procedures for handling and disposal of anticancer drugs should be followed
  • Aseptic technique must be strictly observed since no preservative or bacteriostatic agent is present in MARQIBO
  • Do not use with in-line filters. Do not mix with other drugs
Recommended dose modifications for peripheral neuropathy related to MARQIBO

* Grading based on the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v3.0.
Self-care ADL: refers to bathing, dressing and undressing, feeding self, using the toilet, taking medications, and not bedridden.
Instrumental ADL: refers to preparing meals, shopping for groceries and clothes, using telephone, managing money, etc


Select Important Safety Information

  • Anticipate, monitor for, and manage tumor lysis syndrome
  • A prophylactic bowel regimen should be instituted with MARQIBO to prevent constipation, bowel obstruction, and/or paralytic ileus
  • Twenty-eight percent of patients experienced adverse reactions leading to treatment discontinuation. The most common adverse reactions that caused treatment discontinuation were peripheral neuropathy (10%), leukemia-
    related (7%), and tumor lysis syndrome (2%)